Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozorakimab (MEDI3506), a potent, human anti-IL-33 monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: England, Elizabeth, Rees, D. Gareth, Scott, Ian Christopher, Carmen, Sara, Chan, Denice T. Y., Chaillan Huntington, Catherine E., Houslay, Kirsty F., Erngren, Teodor, Penney, Mark, Majithiya, Jayesh B., Rapley, Laura, Sims, Dorothy A., Hollins, Claire, Hinchy, Elizabeth C., Strain, Martin D., Kemp, Benjamin P., Corkill, Dominic J., May, Richard D., Vousden, Katherine A., Butler, Robin J., Mustelin, Tomas, Vaughan, Tristan J., Lowe, David C., Colley, Caroline, Cohen, E. Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276851/
https://www.ncbi.nlm.nih.gov/pubmed/37330528
http://dx.doi.org/10.1038/s41598-023-36642-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276851/
https://www.ncbi.nlm.nih.gov/pubmed/37330528
http://dx.doi.org/10.1038/s41598-023-36642-y

Ejemplares similares